STM 434

Ligand id: 8991

Name: STM 434

No information available.
Summary of Clinical Use
STM 434 is being evaluated in Phase I clinical trial (NCT02262455) for its potential antineoplastic activity against ovarian cancer and other solid tumours. In October 2015, the US FDA Office of Orphan Products Development (OOPD) granted this therapeutic orphan drug designation for the treatment of ovarian cancer.
Mechanism Of Action and Pharmacodynamic Effects
Activin A (a member of the transforming growth factor β superfamily; HGNC gene name inhibin beta A (INHBA)) , is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival. STM 434 selectively binds to endogenous activin A, effectively neutralising its activity. As a result the activin A/ActRIIB-mediated signaling pathway is not activated and this results in reduced proliferation of activin A-overexpressing tumour cells.